Retension Pharmaceuticals (NASDAQ:RTSN) Stock Rated Outperform in New Coverage at Oppenheimer

Investment analysts at Oppenheimer began coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN) in a research note issued to investors on Tuesday, Benzinga reports. The firm set an “outperform” rating and a $50.00 price target on the stock. Oppenheimer‘s target price would indicate a potential upside of 319.82% from the company’s current price.

Separately, Guggenheim began coverage on shares of Retension Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $55.00 price objective for the company. Two analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $52.50.

Retension Pharmaceuticals Price Performance

RTSN traded up $0.61 during trading on Tuesday, hitting $11.91. The company’s stock had a trading volume of 44,720 shares, compared to its average volume of 105,304. Retension Pharmaceuticals has a twelve month low of $9.66 and a twelve month high of $18.64.

Insider Activity

In other news, CEO Eric Keller bought 20,800 shares of Retension Pharmaceuticals stock in a transaction dated Tuesday, October 13th. The stock was bought at an average cost of $12.00 per share, for a total transaction of $249,600.00. Following the purchase, the chief executive officer directly owned 423,377 shares in the company, valued at approximately $5,080,524. This represents a 5.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Franklin Berger bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average cost of $12.00 per share, with a total value of $120,000.00. Following the completion of the transaction, the director directly owned 10,000 shares in the company, valued at $120,000. This represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.